Class-action suit against Canadian medical marijuana producer expands scope

Just Released! Get realistic market forecasts, state-by-state insights and benchmarks with the new 2024 MJBiz Factbook member program, now with quarterly updates. Make informed decisions.

The scope of a class-action lawsuit targeting Organigram has been expanded to cover allegations that the cultivator’s pesticide-tainted medical marijuana made patients sick before it was recalled, according to CBC News.

The initial suit alleged that Organigram’s “design, development, testing, manufacturing, distribution, sale and marketing of its purported organic medical cannabis were negligent” and that the MMJ was “unsafe and harmful,” the news outlet reported.

The recall affected 3,895 customers and involved 392 kilograms of dried marijuana and 33 liters of cannabis oil.

Organigram’s product was marketed as “100% organic cannabis” when the discovery of unauthorized pesticides prompted the recall. The company lost its organic certification.

Organigram said it conducted an “extensive investigation” but was unable to determine how the banned pesticide myclobutanil ended up in its cannabis.

Amid calls for stricter product testing standards, Health Canada started unannounced inspections at licensed cannabis cultivators in February to ensure that only registered pesticides are used.

There have been eight medical marijuana recalls in Canada this year.

To sign up for our weekly Canada marijuana business newsletter, click here.